Ost-müük Synaptogenix, Inc. - SNPX CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | - | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024874% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.002651% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | N/A |
| Avatud* | N/A |
| Aastane muutus* | N/A |
| Päeva ulatus* | N/A |
| 52 nädala ulatus | 0.80-8.75 |
| Keskmine maht (10 päeva) | 65.35K |
| Keskmine maht (3 kuud) | 1.74M |
| Turukapitalisatsioon | 6.08M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 7.36M |
| Tulu | N/A |
| EPS | -0.83 |
| Dividendid (% kasumist) | N/A |
| Beeta | -100.00K |
| Järgmine tuluaruande kuupäev | N/A |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|
Synaptogenix, Inc. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 12.6183 | 12.8564 | 15.5135 | 11.1494 |
| Müük/Üldine/admin kulud, kokku | 8.28189 | 8.08738 | 10.9725 | 6.26383 |
| Uuringud ja arendus | 4.33641 | 3.06903 | 4.54095 | 4.88556 |
| Tulud majandustegevusest | -12.6183 | -12.8564 | -15.5135 | -11.1494 |
| Intressitulud (kulu), muud tulud, neto | 0.00711 | 0.15321 | 0.37871 | 0.12711 |
| Netotulu enne makse | -12.6112 | -12.7032 | -15.1348 | -11.0223 |
| Netotulu pärast makse | -12.6112 | -12.7032 | -15.1348 | -11.0223 |
| Netotulu enne erikulusid | -12.6112 | -12.7032 | -15.1348 | -11.0223 |
| Netotulu | -12.6112 | -12.7032 | -15.1348 | -11.0223 |
| Arvestatav tulu, v a erikulud | -12.6112 | -15.1302 | -15.1348 | -11.0223 |
| Arvestatav tulu, koos erikuludega | -12.6112 | -15.1302 | -15.1348 | -11.0223 |
| Jaotamisele kuuluv netotulu | -12.6112 | -15.1302 | -15.1348 | -11.0223 |
| Keskmine jaotamisele kuuluv aktsia kohta | 5.0151 | 1.25758 | 1.32211 | 1.32211 |
| Jaotatav EPS, v a erakorralised kulud | -2.51465 | -12.0312 | -11.4474 | -8.33687 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -2.51465 | -10.6794 | -11.4474 | -8.33687 |
| Ootamatud kulutused (tulu) | 0 | 1.7 | ||
| Total Adjustments to Net Income | -2.427 |
| Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 3.16721 | 3.79639 | 3.28253 | 4.23856 | 2.92938 |
| Müük/Üldine/admin kulud, kokku | 1.68251 | 1.85529 | 1.79646 | 2.87693 | 2.09266 |
| Uuringud ja arendus | 1.48469 | 1.9411 | 1.48607 | 1.36164 | 0.83672 |
| Tulud majandustegevusest | -3.16721 | -3.79639 | -3.28253 | -4.23856 | -2.92938 |
| Intressitulud (kulu), muud tulud, neto | 0.14073 | 0.04449 | 0.00461 | 0.00252 | 0.00245 |
| Netotulu enne makse | -3.02648 | -3.7519 | -3.27792 | -4.23605 | -2.92693 |
| Netotulu pärast makse | -3.02648 | -3.7519 | -3.27792 | -4.23605 | -2.92693 |
| Netotulu enne erikulusid | -3.02648 | -3.7519 | -3.27792 | -4.23605 | -2.92693 |
| Netotulu | -3.02648 | -3.7519 | -3.27792 | -4.23605 | -2.92693 |
| Arvestatav tulu, v a erikulud | -3.02648 | -3.7519 | -3.27792 | -4.23605 | -2.92693 |
| Arvestatav tulu, koos erikuludega | -3.02648 | -3.7519 | -3.27792 | -4.23605 | -2.92693 |
| Jaotamisele kuuluv netotulu | -3.02648 | -3.7519 | -3.27792 | -4.23605 | -2.92693 |
| Keskmine jaotamisele kuuluv aktsia kohta | 6.988 | 6.9594 | 6.9392 | 6.7998 | 6.1966 |
| Jaotatav EPS, v a erakorralised kulud | -0.4331 | -0.53911 | -0.47238 | -0.62297 | -0.47234 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Jaotamisele kuuluv normaal-EPS | -0.4331 | -0.53911 | -0.47238 | -0.62297 | -0.47234 |
| Ootamatud kulutused (tulu) | 0 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Käibevarad kokku | 35.5042 | 6.72879 | 17.8762 | 29.4575 |
| Raha ja lühiajalised investeeringud | 34.214 | 5.79506 | 17.382 | 28.8542 |
| Raha ja ekvivalendid | 34.214 | 5.79506 | 17.382 | 28.8542 |
| Prepaid Expenses | 1.29023 | 0.80629 | 0.49411 | 0.60332 |
| Total Assets | 35.5247 | 6.751 | 17.8978 | 29.4784 |
| Property/Plant/Equipment, Total - Net | 0.02045 | 0.02221 | 0.02167 | 0.02084 |
| Total Current Liabilities | 1.99491 | 1.61249 | 0.47906 | 2.95708 |
| Accounts Payable | 1.29651 | 1.26034 | 0.41308 | 2.89858 |
| Accrued Expenses | 0.69841 | 0.35215 | 0.06598 | 0.05849 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.99491 | 1.61249 | 0.47906 | 2.95708 |
| Total Long Term Debt | 0 | 0 | 0 | 0 |
| Total Equity | 33.5298 | 5.13851 | 17.4188 | 26.5213 |
| Common Stock | 0.00067 | 0.0005 | 0.00131 | 0.00129 |
| Additional Paid-In Capital | 47.6707 | 6.66848 | 106.234 | 100.202 |
| Retained Earnings (Accumulated Deficit) | -14.1417 | -1.53047 | -88.8168 | -73.6821 |
| Total Liabilities & Shareholders’ Equity | 35.5247 | 6.751 | 17.8978 | 29.4784 |
| Total Common Shares Outstanding | 6.73018 | 1.25758 | 1.32211 | 1.32211 |
| Laekumata arved, neto | 0.12745 | |||
| Other Equity, Total | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 32.3342 | 35.5042 | 32.3402 | 32.9402 | 16.3257 |
| Raha ja lühiajalised investeeringud | 31.2817 | 34.214 | 31.2946 | 31.7021 | 14.8484 |
| Raha ja ekvivalendid | 31.2817 | 34.214 | 31.2946 | 31.7021 | 14.8484 |
| Laekumata arved, neto | 0 | 0 | |||
| Prepaid Expenses | 1.05247 | 1.29023 | 1.04551 | 1.23816 | 1.47723 |
| Total Assets | 32.3533 | 35.5247 | 32.3586 | 32.96 | 16.3466 |
| Property/Plant/Equipment, Total - Net | 0.01913 | 0.02045 | 0.01849 | 0.01973 | 0.02097 |
| Total Current Liabilities | 0.66934 | 1.99491 | 1.00733 | 0.76997 | 0.93744 |
| Accounts Payable | 0.40135 | 1.29651 | 0.93538 | 0.64816 | 0.75896 |
| Accrued Expenses | 0.26799 | 0.69841 | 0.07195 | 0.12181 | 0.17848 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 0.66934 | 1.99491 | 1.00733 | 0.76997 | 0.93744 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 31.684 | 33.5298 | 31.3513 | 32.19 | 15.4092 |
| Common Stock | 0.00068 | 0.00067 | 0.00062 | 0.0006 | 0.0014 |
| Additional Paid-In Capital | 49.1029 | 47.6707 | 41.2563 | 39.1681 | 20.0927 |
| Retained Earnings (Accumulated Deficit) | -17.4196 | -14.1417 | -9.90563 | -6.97869 | -4.68485 |
| Total Liabilities & Shareholders’ Equity | 32.3533 | 35.5247 | 32.3586 | 32.96 | 16.3466 |
| Total Common Shares Outstanding | 6.80965 | 6.73018 | 6.13697 | 6.0388 | 3.50813 |
- Aastas
- Kvartalis
| 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|
| Netotulu/algväärtus | -12.6112 | -12.7032 | -15.1348 | -11.0223 |
| Raha majandustegevusest | -8.71073 | -8.1024 | -11.8868 | -7.69677 |
| Raha majandustegevusest | 0.00497 | 0.00487 | 0.00439 | 0.003 |
| Mittelikviidsed varad | 3.86958 | 3.90212 | 5.61236 | 2.21661 |
| Muutused tööjõus | 0.02593 | 0.69381 | -2.36881 | 1.10591 |
| Tulu investeeringutelt | -0.0032 | -0.00541 | -0.00521 | -0.00319 |
| Kapitalikulutused | -0.0032 | -0.00541 | -0.00521 | -0.00319 |
| Rahavood investeeringutelt | 37.1329 | -3.47917 | 0.41984 | 20.441 |
| Aktsiate emiteerimine (tagasiost), neto | 37.1344 | 16.5242 | 0.41984 | 20.441 |
| Rahaline kogumuutus | 28.4189 | -11.587 | -11.4722 | 12.7411 |
| Rahavoogudesse investeerimine | -0.00153 | -20.0034 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -3.27792 | -12.6112 | -8.37515 | -5.44822 | -3.15438 |
| Cash From Operating Activities | -3.48541 | -8.71073 | -6.66556 | -5.58532 | -3.58672 |
| Cash From Operating Activities | 0.00132 | 0.00497 | 0.00373 | 0.00249 | 0.00125 |
| Non-Cash Items | 0.87901 | 3.86958 | 2.4228 | 1.1348 | 0.91241 |
| Changes in Working Capital | -1.08781 | 0.02593 | -0.71694 | -1.27439 | -1.34599 |
| Cash From Investing Activities | -0.0032 | 0 | 0 | 0 | |
| Capital Expenditures | -0.0032 | 0 | 0 | 0 | |
| Cash From Financing Activities | 0.55315 | 37.1329 | 32.1651 | 31.4923 | 12.6401 |
| Financing Cash Flow Items | 0 | -0.00153 | -0.00153 | 0.12592 | 0.12745 |
| Issuance (Retirement) of Stock, Net | 0.55315 | 37.1344 | 32.1667 | 31.3664 | 12.5127 |
| Net Change in Cash | -2.93226 | 28.4189 | 25.4996 | 25.907 | 9.0534 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Alpha Capital Aktiengesellschaft | Holding Company | 4.1055 | 301977 | -29305 | 2021-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.0271 | 222654 | 159 | 2022-12-31 | LOW |
| Intracoastal Capital, L.L.C. | Corporation | 2.4304 | 178765 | 178365 | 2022-12-31 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8472 | 62316 | -159 | 2022-12-31 | LOW |
| Perry (George) | Individual Investor | 0.5438 | 40000 | 40000 | 2021-07-13 | |
| Silverman (Joshua) | Individual Investor | 0.5199 | 38238 | 0 | 2023-03-15 | LOW |
| Alkon (Daniel L M.D.) | Individual Investor | 0.4833 | 35547 | 0 | 2023-03-15 | MED |
| Citadel Advisors LLC | Hedge Fund | 0.4655 | 34238 | 34238 | 2022-12-31 | HIGH |
| Weinstein (Robert) | Individual Investor | 0.4513 | 33197 | -1 | 2023-03-15 | LOW |
| Singer (William S) | Individual Investor | 0.4487 | 33000 | 0 | 2023-03-15 | HIGH |
| Tuchman (Alan J) | Individual Investor | 0.4487 | 33000 | 0 | 2023-03-15 | HIGH |
| Cannell & Co. | Investment Advisor | 0.4079 | 30000 | -46220 | 2022-12-31 | LOW |
| Bernstein (Bruce T.) | Individual Investor | 0.3749 | 27578 | 0 | 2023-03-15 | LOW |
| Schechter (Jonathan L) | Individual Investor | 0.3705 | 27250 | 0 | 2023-03-15 | MED |
| Diametric Capital | Investment Advisor/Hedge Fund | 0.3609 | 26549 | -1172 | 2022-09-30 | HIGH |
| Platform Technology Partners LLC | Investment Advisor | 0.3418 | 25138 | 9106 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2733 | 20100 | 0 | 2022-12-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.2065 | 15188 | 348 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.1835 | 13500 | -3000 | 2022-12-31 | HIGH |
| Advisor Group, Inc | Investment Advisor | 0.1244 | 9148 | 8600 | 2022-12-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Synaptogenix, Inc. Company profile
Ettevõttest Synaptogenix, Inc.
Synaptogenix, Inc., varem Neurotrope BioScience, Inc. on biofarmatseutiline ettevõte. Ettevõte keskendub peamiselt neurodegeneratiivsete haiguste ja arenguhäiretega patsientidele mõeldud ravimite väljatöötamisele. Ettevõte arendab tooteplatvormi, mis põhineb ravimikandidaadil nimega Bryostatin-1, mis sünteesitakse looduslikust tootest (bryostatin), mis on isoleeritud mereselgrootute organismist, Alzheimeri tõve raviks. Selle juhtiv tootekandidaat on brüostatiin-1. Bryostatin-1 on proteiinkinaas C Epsilon (PKC e), a ja e aktivaator, mis algselt töötati välja potentsiaalse vähivastase ravimina. Ettevõte hindab ka brüostatiini terapeutilisi rakendusi teiste neurodegeneratiivsete või kognitiivsete haiguste ja funktsioonihäirete puhul, nagu Fragile X sündroom, hulgiskleroos ja Niemann-Picki C-tüüpi haigus, mis on läbinud prekliinilised katsed.
| Industry: | Biotechnology & Medical Research (NEC) |
1185 Avenue Of The Americas, 3Rd Floor
NEW YORK
NEW YORK 10036
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com